Lexaria Bioscience R&D Surges in Q2 2025
Ticker: LEXX · Form: 10-Q · Filed: Apr 14, 2025
Sentiment: neutral
Topics: 10-Q, R&D, revenue, pharmaceuticals
TL;DR
Lexaria Bioscience Q2: R&D up to $4.5M, IP revenue $1.58M. Assets $220M.
AI Summary
Lexaria Bioscience Corp. filed its 10-Q for the period ending February 28, 2025. The company reported total assets of $220 million. For the six months ended February 28, 2025, Lexaria Bioscience incurred research and development expenses of $4.52 million, a significant increase from $2.45 million in the same period last year. Intellectual property licensing revenue for the six months ended February 28, 2025, was $1.58 million.
Why It Matters
Increased R&D spending suggests Lexaria Bioscience is investing heavily in developing new products or technologies, which could lead to future growth or significant cash burn.
Risk Assessment
Risk Level: medium — The company's significant increase in R&D expenses without a corresponding increase in revenue could indicate higher financial risk if new developments do not materialize into profitable products.
Key Numbers
- $220.0M — Total Assets (As of February 28, 2025)
- $4.52M — R&D Expenses (YTD) (Six months ended February 28, 2025)
- $1.58M — IP Licensing Revenue (YTD) (Six months ended February 28, 2025)
- $2.45M — R&D Expenses (Prior YTD) (Six months ended February 29, 2024)
Key Players & Entities
- Lexaria Bioscience Corp. (company) — Filer of the 10-Q
- February 28, 2025 (date) — End of reporting period
- $220 million (dollar_amount) — Total assets
- $4.52 million (dollar_amount) — R&D expenses for six months ended Feb 28, 2025
- $2.45 million (dollar_amount) — R&D expenses for six months ended Feb 29, 2024
- $1.58 million (dollar_amount) — Intellectual property licensing revenue for six months ended Feb 28, 2025
FAQ
What was Lexaria Bioscience Corp.'s total revenue for the six months ended February 28, 2025?
The filing indicates intellectual property licensing revenue of $1.58 million for the six months ended February 28, 2025.
How did Lexaria Bioscience Corp.'s research and development expenses change compared to the prior year's period?
R&D expenses increased to $4.52 million for the six months ended February 28, 2025, from $2.45 million for the six months ended February 29, 2024.
What is the total reported asset value for Lexaria Bioscience Corp. as of February 28, 2025?
The company reported total assets of $220 million as of February 28, 2025.
What is the fiscal year-end for Lexaria Bioscience Corp.?
Lexaria Bioscience Corp.'s fiscal year ends on August 31st.
What is the primary business segment for Lexaria Bioscience Corp. according to the SIC code?
The Standard Industrial Classification (SIC) code indicates the company operates in Pharmaceutical Preparations [2834].
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 14, 2025 regarding Lexaria Bioscience Corp. (LEXX).